Hitgen Ltd., of Chengdu, China, said it inked a collaborative agreement with the Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr), to focus on oncology, regenerative medicine and virology. Hitgen will utilize its technology platform to identify new small-molecule leads for therapeutic targets identified by the collaboration. TSRI and Calibr will provide target materials and expertise to prosecute drug targets of interest.